We are live on
!
Find out more
Royalty Pharma
RPRX
RPRX
587 hedge funds and large institutions have $17B invested in Royalty Pharma in 2026 Q1 according to their latest regulatory filings, with 116 funds opening new positions, 224 increasing their positions, 180 reducing their positions, and 59 closing their positions.
New
Increased
Maintained
Reduced
Closed
188% more call options, than puts
Call options by funds: $42.8M | Put options by funds: $14.9M
97% more first-time investments, than exits
New positions opened: 116 | Existing positions closed: 59
24% more repeat investments, than reductions
Existing positions increased: 224 | Existing positions reduced: 180
23% more capital invested
Capital invested by funds: $13.8B → $17B (+$3.18B)
9% more funds holding
Funds holding: 538 → 587 (+49)
7% more funds holding in top 10
Funds holding in top 10: 14 → 15 (+1)
0.28% less ownership
Funds ownership: 83.75% → 83.48% (-0.28%)
Holders
587
Holders Change
+49
Holders Change %
+9.11%
% of All Funds
7.22%
Holding in Top 10
15
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+7.14%
% of All Funds
0.18%
New
116
Increased
224
Reduced
180
Closed
59
Calls
$42.8M
Puts
$14.9M
Net Calls
+$27.9M
Net Calls Change
+$24.3M
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$513M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$187M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$114M |
| 4 |
Jane Street
New York
|
-$112M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$57.1M |
